[
    [
        {
            "time": "2023-10-01",
            "original_text": "Is This Chinese Biopharma Stock Still a Buy?",
            "features": {
                "keywords": [
                    "Chinese",
                    "Biopharma",
                    "Stock",
                    "Buy"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "biopharma"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 3,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "These 3 High-Dividend Stocks Have Cathie Wood's Seal of Approval",
            "features": {
                "keywords": [
                    "High-Dividend",
                    "Stocks",
                    "Cathie Wood",
                    "Approval"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "dividend stocks",
                    "growth"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 10,
                "Source_Recency": 6
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "Novartis appoints Rob Kowalski as Chief People & Organization Officer",
            "features": {
                "keywords": [
                    "Novartis",
                    "appoints",
                    "Rob Kowalski",
                    "Chief People & Organization Officer"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals",
                    "management"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        }
    ]
]